IL-36γ enhanced bactericidal effects of macrophages to Mycobacterium tuberculosis via the IFN-γ/HIF-1ɑ/glycolysis pathway.

IL-36γ enhanced bactericidal effects of macrophages to Mycobacterium tuberculosis via the IFN-γ/HIF-1ɑ/glycolysis pathway.

Publication date: May 04, 2026

IL-36γ coordinates macrophage activation and is essential for defense against Mycobacterium tuberculosis (Mtb), but the mechanisms remains poorly understood. Aerobic glycolysis plays a critical role in macrophages intrinsic control of Mtb infection. This study aimed to investigate the potential effects of IL-36γ on macrophages energy metabolism transformation from mitochondrial oxidative phosphorylation to aerobic glycolysis in response to Mtb infection. The expression of IL-36γ in lung tissues, PBMCs and serum was analyzed using Immunohistochemistry, ELISA and RT-qPCR, while the role and mechanism of IL-36γ on macrophages energy metabolism transformation duing Mtb infection were investigated by RT-qPCR, ELISA, Western blot and colony-forming unit assay. We demonstrated IL-36γ enhanced the aerobic glycolysis, and downregulated the mitochondrial oxidative phosphorylation in Mtb infected macrophages. Furthermore, IL-36γ upregulated the expression of HIF-1α and IFN-γ in macrophages through the NF-_705B/ERK/JNK signaling pathway, especially in macrophages infected with Mtb, where it induced the expression of large amounts of HIF-1α and IFN-γ. Moreover, IL-36γ promoted aerobic glycolysis through inducing the expression of HIF-1α in macrophages during Mtb infection. Meanwhile, HIF-1α was required for IL-36γ-mediated control of Mtb infection. Interestingly, the expression of IL-36γ was increased in lung tissues, PBMCs and serum from patients with active pulmonary tuberculosis and correlated with monocytes/macrophages immune response and IFN-γ levels, displayed an appreciable diagnostic value. IL-36γ enhanced bactericidal effects of macrophages to Mycobacterium tuberculosis via the IFN-γ/HIF-1α/ glycolysis pathway. IL-36γ may be a potential treatment target and useful biomarker for tuberculosis.

Open Access PDF

Concepts Keywords
Bactericidal Aerobic glycolysis
Biomarker Biomarker
Promoted HIF-1α
Tuberculosis IFN-γ
IL-36γ
Tuberculosis

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
pathway REACTOME Glycolysis
disease MESH infection
pathway REACTOME Metabolism
pathway KEGG Oxidative phosphorylation
disease MESH pulmonary tuberculosis
pathway REACTOME Reproduction
disease MESH included
drug DRUGBANK Coenzyme M
disease MESH death
drug DRUGBANK ATP
drug DRUGBANK Oxygen
disease MESH hypoxia
disease MESH pleural effusion
drug DRUGBANK Nitric Oxide
pathway REACTOME Antimicrobial peptides
pathway REACTOME Autophagy
drug DRUGBANK Dextrose unspecified form
disease MESH cancer
disease MESH autoimmune diseases
drug DRUGBANK Flunarizine
drug DRUGBANK Formaldehyde
disease MESH image
drug DRUGBANK Dimethyl sulfoxide
disease MESH PBS
drug DRUGBANK Water
drug DRUGBANK Saquinavir
disease MESH MDM
pathway REACTOME Release
disease MESH necrosis
drug DRUGBANK Dinoprostone
pathway REACTOME Translation
drug DRUGBANK Huperzine B
drug DRUGBANK Etoperidone
disease MESH infectious diseases
drug DRUGBANK Guanosine
drug DRUGBANK Succinic acid
disease MESH Tuberculous Pleurisy
disease MESH Dis
pathway KEGG Cholesterol metabolism
disease MESH colitis
drug DRUGBANK Acetate ion
drug DRUGBANK Ranitidine
disease MESH weight loss
disease MESH obesity
disease MESH prediabetes
disease MESH Rheumatoid Arthritis
pathway KEGG Rheumatoid arthritis
disease MESH Inflammation
disease MESH Psoriasis
disease MESH Atopic Dermatitis
drug DRUGBANK Pyruvaldehyde
disease MESH Park
disease MESH Atrophy
disease MESH Granulomas
disease MESH SARS CoV 2 Infection
disease MESH acute pancreatitis
disease MESH Tam
drug DRUGBANK Carboxyamidotriazole
disease MESH shock
pathway REACTOME Apoptosis
drug DRUGBANK Proline
drug DRUGBANK Albendazole

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *